Shopping Cart
Remove All
Your shopping cart is currently empty
Anrukinzumab (Synonyms: IMA-638)
Catalog No. T76906 Copy Product Info
🥰Excellent
Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Anrukinzumab
Copy Product Info🥰Excellent
Catalog No. T76906
Synonyms IMA-638
Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Anrukinzumab
Cas No. 910649-32-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.0% (SDS-PAGE); 98.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma. |
| In vivo | Methods: Anrukinzumab (10 mg/kg, intravenous injection, single dose) was used to treat adult male cynomolgus monkeys with lung inflammation to observe its therapeutic effect. Results: Anrukinzumab was able to reduce the total cell count, eosinophil count, and neutrophil count in bronchoalveolar lavage (BAL) fluid. [1] |
| Synonyms | IMA-638 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-13 |
| Molecular Weight | 145.38 kDa |
| Cas No. | 910649-32-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Anrukinzumab | purchase Anrukinzumab | Anrukinzumab cost | order Anrukinzumab | Anrukinzumab in vivo | Anrukinzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.